BRPI0820085A2 - compostos contendo quinoxalina como inibidores de vírus da hepatite c - Google Patents

compostos contendo quinoxalina como inibidores de vírus da hepatite c

Info

Publication number
BRPI0820085A2
BRPI0820085A2 BRPI0820085A BRPI0820085A BRPI0820085A2 BR PI0820085 A2 BRPI0820085 A2 BR PI0820085A2 BR PI0820085 A BRPI0820085 A BR PI0820085A BR PI0820085 A BRPI0820085 A BR PI0820085A BR PI0820085 A2 BRPI0820085 A2 BR PI0820085A2
Authority
BR
Brazil
Prior art keywords
quinoxaline
hepatitis
containing compounds
virus inhibitors
virus
Prior art date
Application number
BRPI0820085A
Other languages
English (en)
Inventor
Sun Or Yat
Gai Yonghua
Wang Zhe
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Publication of BRPI0820085A2 publication Critical patent/BRPI0820085A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0820085A 2007-11-14 2008-11-14 compostos contendo quinoxalina como inibidores de vírus da hepatite c BRPI0820085A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98795807P 2007-11-14 2007-11-14
US2545808P 2008-02-01 2008-02-01
PCT/US2008/083541 WO2009064975A1 (en) 2007-11-14 2008-11-14 Quinoxaline-containing compounds as hepatitis c virus inhibitors

Publications (1)

Publication Number Publication Date
BRPI0820085A2 true BRPI0820085A2 (pt) 2019-09-24

Family

ID=40639146

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820085A BRPI0820085A2 (pt) 2007-11-14 2008-11-14 compostos contendo quinoxalina como inibidores de vírus da hepatite c

Country Status (25)

Country Link
US (2) US8324155B2 (pt)
EP (1) EP2219453B1 (pt)
JP (1) JP5479354B2 (pt)
KR (1) KR20100098527A (pt)
CN (1) CN101909446A (pt)
AR (1) AR069464A1 (pt)
AU (1) AU2008322537A1 (pt)
BR (1) BRPI0820085A2 (pt)
CA (1) CA2705807A1 (pt)
CL (1) CL2008003384A1 (pt)
CO (1) CO6280441A2 (pt)
CR (1) CR11499A (pt)
DO (1) DOP2010000143A (pt)
EC (1) ECSP10010254A (pt)
ES (1) ES2476257T3 (pt)
IL (1) IL205611A0 (pt)
MX (1) MX2010005262A (pt)
MY (1) MY155851A (pt)
PE (2) PE20091212A1 (pt)
RU (1) RU2493160C2 (pt)
TW (1) TWI431011B (pt)
UA (1) UA102677C2 (pt)
UY (1) UY31470A1 (pt)
WO (1) WO2009064975A1 (pt)
ZA (1) ZA201003363B (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
AR057456A1 (es) 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
US8278322B2 (en) 2005-08-01 2012-10-02 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
CA2667165A1 (en) 2006-10-24 2008-05-02 Merck & Co., Inc. Hcv ns3 protease inhibitors
CN101583372A (zh) 2006-10-24 2009-11-18 默克公司 Hcv ns3蛋白酶抑制剂
US8138164B2 (en) 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
WO2008057208A2 (en) 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
JP5268927B2 (ja) 2006-10-27 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション Hcvns3プロテアーゼ阻害剤
US8101595B2 (en) 2006-12-20 2012-01-24 Istituto di Ricerche di Biologia Molecolare P. Angletti SpA Antiviral indoles
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
AU2008277442A1 (en) 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis C infections
CN101754974B (zh) 2007-07-19 2016-02-03 Msd意大利有限公司 作为抗病毒剂的大环化合物
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
US8030307B2 (en) * 2007-11-29 2011-10-04 Enanta Pharmaceuticals, Inc. Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease
WO2009079353A1 (en) 2007-12-14 2009-06-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic hcv serine protease inhibitors
JP2011506472A (ja) 2007-12-14 2011-03-03 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状オキシミルc型肝炎セリンプロテアーゼ阻害剤
US8283309B2 (en) 2007-12-20 2012-10-09 Enanta Pharmaceuticals, Inc. Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors
CA2713005A1 (en) * 2008-01-24 2009-07-30 Enanta Pharmaceuticals, Inc. Difluorinated tripeptides as hcv serine protease inhibitors
CN102014911A (zh) 2008-04-28 2011-04-13 默沙东公司 Hcv ns3蛋白酶抑制剂
WO2009134987A1 (en) 2008-04-30 2009-11-05 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors
ES2392611T3 (es) 2008-07-22 2012-12-12 Merck Sharp & Dohme Corp. Compuestos de quinoxalina macrocíclica como inhibidores de la proteasa NS3 del VHC
CA2761650C (en) 2009-05-13 2015-05-26 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis c virus inhibitors
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
US9193740B2 (en) 2009-10-19 2015-11-24 Enanta Pharmaceuticals, Inc. Bismacrocyclic compounds as hepatitis C virus inhibitors
EA201201031A1 (ru) 2010-01-25 2013-02-28 Энанта Фармасьютиклз, Инк. Ингибиторы вируса гепатита с
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CA2788155C (en) 2010-01-27 2018-04-24 AB Pharma Ltd. Polyheterocyclic compounds highly potent as hcv inhibitors
US9127021B2 (en) 2010-04-09 2015-09-08 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2575819A4 (en) 2010-06-04 2013-11-27 Enanta Pharm Inc INHIBITORS OF HEPATITIS C VIRUS
TWI523658B (zh) * 2010-09-21 2016-03-01 安塔製藥公司 巨環脯胺酸衍生之hcv絲胺酸蛋白酶抑制劑
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8962810B2 (en) 2011-06-16 2015-02-24 AB Pharma Ltd. Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof
AR091279A1 (es) * 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
IN2014MN02652A (pt) 2012-06-08 2015-08-21 Gilead Sciences Inc
SI2859009T1 (sl) * 2012-06-08 2017-12-29 Gilead Sciences, Inc. Makrociklični inhibitorji flaviviridae virusov
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
JP6154474B2 (ja) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company C型肝炎ウイルス阻害剤
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
JP6511432B2 (ja) 2013-03-15 2019-05-15 ギリアード サイエンシーズ, インコーポレイテッド C型肝炎ウイルスの大環状二環式阻害剤
CA2934537C (en) * 2013-12-23 2022-08-16 Gilead Sciences, Inc. Synthesis of an antiviral compound
CA2934049A1 (en) * 2013-12-23 2015-07-02 Gilead Sciences, Inc. Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
CN107266529A (zh) * 2016-04-08 2017-10-20 上海长森药业有限公司 一类抑制丙肝病毒的大环状杂环化合物及其制备和用途
RU2650610C1 (ru) * 2017-02-28 2018-04-16 Васильевич Иващенко Александр Противовирусная композиция и способ ее применения
CN107987083A (zh) * 2017-11-24 2018-05-04 江苏亚盛医药开发有限公司 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1047947A1 (zh) 2000-04-05 2003-03-14 Schering Corporation 包含n-环状p2部分的丙型肝炎病毒的大环ns3-丝氨酸蛋白酶抑制剂
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7176208B2 (en) * 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
JO2785B1 (en) * 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
AR057456A1 (es) * 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
EP2305696A3 (en) * 2005-07-25 2011-10-12 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
US8278322B2 (en) * 2005-08-01 2012-10-02 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
GB0609492D0 (en) * 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) * 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
UY30437A1 (es) 2006-06-26 2008-01-31 Enanta Pharm Inc Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
US7582605B2 (en) 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
JP5268927B2 (ja) * 2006-10-27 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション Hcvns3プロテアーゼ阻害剤
US20080267917A1 (en) 2007-04-26 2008-10-30 Deqiang Niu N-functionalized amides as hepatitis c serine protease inhibitors
US8377872B2 (en) 2007-04-26 2013-02-19 Enanta Pharmaceuticals, Inc. Cyclic P3 tripeptide hepatitis C serine protease inhibitors
WO2008134397A1 (en) 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Aza-tripeptide hepatitis c serine protease inhibitors
CN101754974B (zh) 2007-07-19 2016-02-03 Msd意大利有限公司 作为抗病毒剂的大环化合物
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
JP2011503201A (ja) 2007-11-14 2011-01-27 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状テトラゾリルc型肝炎セリンプロテアーゼ阻害剤
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
CA2708150A1 (en) 2007-12-05 2009-06-18 Enanta Pharmaceuticals, Inc. Fluorinated tripeptide hcv serine protease inhibitors
MX2010006209A (es) 2007-12-05 2010-08-10 Enanta Pharm Inc Derivados de quinoxalinilo.
WO2009079353A1 (en) 2007-12-14 2009-06-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic hcv serine protease inhibitors
JP2011506472A (ja) 2007-12-14 2011-03-03 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状オキシミルc型肝炎セリンプロテアーゼ阻害剤
US8283309B2 (en) 2007-12-20 2012-10-09 Enanta Pharmaceuticals, Inc. Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors

Also Published As

Publication number Publication date
ECSP10010254A (es) 2010-07-30
US20100003214A1 (en) 2010-01-07
TW200938550A (en) 2009-09-16
JP5479354B2 (ja) 2014-04-23
US8324155B2 (en) 2012-12-04
IL205611A0 (en) 2010-11-30
CO6280441A2 (es) 2011-05-20
KR20100098527A (ko) 2010-09-07
ZA201003363B (en) 2011-04-28
MY155851A (en) 2015-12-15
HK1146693A1 (en) 2011-07-08
AU2008322537A1 (en) 2009-05-22
PE20091212A1 (es) 2009-09-13
CN101909446A (zh) 2010-12-08
DOP2010000143A (es) 2010-07-31
CA2705807A1 (en) 2009-05-22
RU2010123928A (ru) 2011-12-20
TWI431011B (zh) 2014-03-21
US8951998B2 (en) 2015-02-10
CL2008003384A1 (es) 2009-12-11
MX2010005262A (es) 2010-08-10
WO2009064975A1 (en) 2009-05-22
AR069464A1 (es) 2010-01-27
JP2011505339A (ja) 2011-02-24
EP2219453B1 (en) 2014-04-09
RU2493160C2 (ru) 2013-09-20
US20130144036A1 (en) 2013-06-06
UA102677C2 (uk) 2013-08-12
ES2476257T3 (es) 2014-07-14
EP2219453A4 (en) 2011-01-19
PE20140189A1 (es) 2014-03-12
UY31470A1 (es) 2009-07-17
CR11499A (es) 2010-10-25
EP2219453A1 (en) 2010-08-25

Similar Documents

Publication Publication Date Title
BRPI0908240A2 (pt) inibidores do vírus da hepatite c
BRPI0907733A2 (pt) Inibidores do vírus da hepatite c
IL205611A0 (en) Quinoxaline-containing compounds as hepatitis c virus inhibitors
BRPI1007836A2 (pt) Inibidores do vírus c da hepatite
BRPI1008846A2 (pt) inibidores do vírus da hepatite c
BRPI1013393A2 (pt) inibidores do vírus da hepatite c
BRPI1014084A2 (pt) inibidores do vírus da hepatite c
BR112012002508A2 (pt) derivados de feniletinila como inibidores de vírus de hepatite c
CY2015012I1 (el) Αναστολεις του ιου της ηπατιτιδας c
DK2242752T3 (da) Imidazolyl-biphenylimidazoler som hepatitis C-virus-inhibitorer
BRPI1010506A2 (pt) "inibidores do vírus da hepatite c"
BRPI0716483A2 (pt) inibidores do vírus da hepatite c
LTPA2016048I1 (lt) Hepatito C viruso replikacijos inhibitoriai
BRPI0821836A2 (pt) Indóis macrocíclicos como inibidores do vírus da hepatite c
DK3192874T3 (da) Virusoprensning
BR112012005438A2 (pt) inibidores de vírus flaviviridae
DK2440545T3 (da) Forbindelser, der er anvendelige til behandling af cancer
EP2344471A4 (en) 7-PIPERIDINALKYL-3,4-dihydroquinolone DERIVATIVE
EP2429568A4 (en) MACROCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS
BRPI0821034A2 (pt) Vírus influenza modificado
EP2496709A4 (en) DETECTION OF A TARGET SEQUENCE WITH A THD PRIMER
BRPI0923034A2 (pt) terapia de combinação para virus da hepatite c
BRPI0818844A2 (pt) Métodos de inibição de infecção viral.
TH105715B (th) สารยับยั้งไวรัสตับอักเสบ c
TH0801000728A (th) สารยับยั้งไวรัสตับอักเสบ c

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.